Is Trending Stock Johnson & Johnson (JNJ) a Buy Now?

Johnson & Johnson (JNJ) shares have outperformed the S&P 500 and its industry over the past month, gaining 8.6%. The company has consistently exceeded consensus revenue and EPS estimates in the last four quarters, with recent positive revisions to earnings estimates for both current and next fiscal years. This fundamental strength, combined with a Zacks Rank #2 (Buy) and a 'B' Zacks Value Style Score indicating it trades at a discount to peers, suggests JNJ is positioned for potential near-term market outperformance.

Analysis

Johnson & Johnson (JNJ) has demonstrated significant relative strength, with its shares returning +8.6% over the past month, substantially outperforming both the S&P 500 composite's +5.9% gain and the broader Zacks Large Cap Pharmaceuticals industry's -0.1% decline. This price momentum is underpinned by positive revisions to earnings estimates and a strong operational track record. Sell-side analysts have increased the consensus EPS estimate for the current fiscal year by +2.4% over the last 30 days to $10.83, implying an +8.5% year-over-year growth. Similarly, estimates for the next fiscal year have been revised upward by +3.2%. This positive sentiment is supported by a consistent history of execution, as JNJ has surpassed consensus revenue and EPS estimates for the past four consecutive quarters, with the most recent report showing a +4.13% revenue surprise. Furthermore, revenue is projected to grow +5.2% in the current fiscal year. Despite the recent stock appreciation, the company's valuation appears reasonable, as indicated by a Zacks Value Style Score of 'B', which suggests it is trading at a discount compared to its peers.

Key Decisions for Investors

• Given the combination of positive earnings estimate revisions, consistent quarterly performance, and recent market outperformance, investors might view the stock as a compelling holding or a candidate for accumulation.
• The stock's valuation, which suggests a discount relative to peers despite an 8.6% monthly gain, could present a favorable entry point for value-oriented investors.
• Investors should monitor upcoming earnings reports to ensure the company delivers on the forecasted +5.2% revenue growth and +8.5% EPS growth for the current fiscal year, which are the core drivers of the current bullish thesis.
• For portfolio allocation, JNJ's pronounced relative strength against a declining pharmaceutical sector could make it an attractive candidate for overweighting within a diversified healthcare exposure.